By Karen E. Roman
Alladapt Immunotherapeutics, Inc., a clinical-stage company which develops therapeutics to address food allergies, announced data from its Phase 1/2 Harmony study which proves that ADP101, a multi-allergen oral immunotherapy (OIT), produced dose-dependent, clinically meaningful responses.
The data was presented at the 2023 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology (ACAAI), which took place from November 9-13, the company said.
ADP101 also generated a favorable safety profile in pediatric patients allergic to one or more of the food sources in the product, the company stated. This OIT simultaneously treats allergy to one or more food allergens like almond, cashew, chicken’s egg, codfish, cow’s milk, hazelnut, and peanut, among others.
“The efficacy analysis was promising,” said Warner Carr, M.D., a primary investigator in the Harmony study. “ADP101 has the potential to transform the value proposition of oral immunotherapy for the treatment of food allergy and expand the patient population that could be treated,” he said.
Editor@Executives-edge.com
